WEST VIRGINIA LEGISLATURE
REGULAR SESSION, 1989

ENROLLED

SENATE BILL NO. 737

(By Senators J. Marchin, et al.)

PASSED February 27, 1989
In Effect July 1, 1989
AN ACT to amend and reenact section twelve-b, article five, chapter thirty of the code of West Virginia, one thousand nine hundred thirty-one, as amended, relating to requirement that prescribing practitioner specify in his or her own handwriting “Brand Necessary” or “Brand Medically Necessary” or other designated language if generic drugs are not to be used to fill a prescription.

Be it enacted by the Legislature of West Virginia:

That section twelve-b, article five, chapter thirty of the code of West Virginia, one thousand nine hundred thirty-one, as amended, be amended and reenacted to read as follows:

ARTICLE 5. PHARMACISTS, ASSISTANT PHARMACISTS AND DRUGSTORES.

§30-5-12b. Definitions; selection of generic drug products.

1 (a) As used in this section:

2 (1) “Brand name” means the proprietary or trade name selected by the manufacturer and placed upon a drug or drug product, its container, label or wrapping at the time of packaging.
(2) "Generic name" means the official title of a drug or drug combination for which a new drug application, or an abbreviated new drug application, has been approved by the United States food and drug administration and is in effect.

(3) "Substitute" means to dispense without the prescriber's express authorization a therapeutically equivalent generic drug product in the place of the drug ordered or prescribed.

(4) "Equivalent" means drugs or drug products which are the same amounts of identical active ingredients and same dosage form, and which will provide essentially the same therapeutic efficacy and toxicity when administered to an individual.

(5) "Practitioner" means a physician, an authorized Type A physician assistant at the direction of his or her supervising physician in accordance with the provisions of section sixteen, article three of this chapter, osteopath, dentist, veterinarian, podiatrist, optometrist or any other person duly licensed to practice and to prescribe drugs under the laws of this state.

(b) A pharmacist who receives a prescription for a brand name drug or drug product shall substitute a less expensive equivalent generic name drug or drug product unless in the exercise of his or her professional judgment the pharmacist believes that the less expensive drug is not suitable for the particular patient: Provided, That no substitution may be made by the pharmacist where the prescribing practitioner indicates that, in his or her professional judgment, a specific brand name drug is medically necessary for a particular patient. Every drug prescription order shall contain an instruction on whether or not an equivalent generic name drug or drug product may be substituted.

A written prescription order shall permit the pharmacist to substitute an equivalent generic name drug or drug product except where the prescribing practitioner has indicated in his or her own handwriting the
words “Brand Necessary” or “Brand Medically Necessary.” The following sentence shall be printed on the prescription form: “This prescription may be filled with a generically equivalent drug product unless the words ‘Brand Necessary’ or the words ‘Brand Medically Necessary’ are written, in the practitioner’s own handwriting, on this prescription form.”

A verbal prescription order shall permit the pharmacist to substitute an equivalent generic name drug or drug product except where the prescribing practitioner or his or her agent shall indicate to the pharmacist that the prescription is “Brand Necessary” or “Brand Medically Necessary.” The pharmacist shall note the instructions on the file copy of the prescription or chart order form.

(c) No person may by trade rule, work rule, contract, or in any other way prohibit, restrict, limit or attempt to prohibit, restrict or limit the making of a generic name substitution under subsection (b) of this section. No employer or his or her agent may use coercion or other means to interfere with the professional judgment of the pharmacist in deciding which generic name drugs or drug products shall be stocked or substituted: Provided, That this section shall not be construed to permit the pharmacist to generally refuse to substitute less expensive therapeutically equivalent generic drugs for brand name drugs, and that any pharmacist so refusing shall be subject to the penalties prescribed in section twenty-two, article five, chapter thirty of this code.

(d) A pharmacist may substitute a drug under subsection (b) of this section only where there will be a savings to the buyer. Where substitution is proper under subsection (b), or where the practitioner prescribes the drug by generic name, the pharmacist shall, consistent with his or her professional judgment, dispense the lowest retail cost, effective brand which is in stock.

(e) All savings in the retail price of the prescription shall be passed on to the purchaser; these savings shall
be equal to the difference between the retail price of the brand name product and the customary and usual price of the generic product substituted therefor:

Provided, That in no event shall such savings be less than the difference in acquisition cost of the brand name product prescribed and the acquisition cost of the substituted product.

(f) Each pharmacy shall maintain a record of any substitution of an equivalent generic name drug product for a prescribed brand name drug product on the file copy of a written or verbal prescription or chart order. Such record shall include the manufacturer and generic name of the drug product selected.

All drugs shall be labeled in accordance with the instructions of the practitioner.

Unless the practitioner directs otherwise, the prescription label on all drugs dispensed by the pharmacist shall indicate the generic name using abbreviations if necessary and the name of the manufacturer. The same notation will be made on the original prescription retained by the pharmacist.

(g) A pharmacist may not dispense a product under the provisions of this section unless the manufacturer has shown that the drug has been manufactured with the following minimum good manufacturing standards and practices by:

(1) Labeling products with the name of the original manufacturer and control number;

(2) Maintaining quality control standards equal to or greater than those of the United States food and drug administration;

(3) Marking products with identification code or monogram; and

(4) Labeling products with an expiration date.

(h) The West Virginia board of pharmacy shall establish by rule a formulary of generic type and brand name drug products which are determined by the board to demonstrate significant biological or
therapeutic inequivalence and which, if substituted, would pose a threat to the health and safety of patients receiving prescription medication. The formulary shall be promulgated by the board within ninety days of the date of passage of this section, and may be amended in accordance with the provisions of chapter twenty-nine-a of this code.

(i) No pharmacist shall substitute a generic named therapeutically equivalent drug product for a prescribed brand name drug product if the brand name drug product or the generic drug type is listed on the formulary established by the West Virginia board of pharmacy pursuant to this article, or is found to be in violation of the requirements of the United States food and drug administration.

(j) Any pharmacist who substitutes any drug shall, either personally or through his or her agent, assistant or employee, notify the person presenting the prescription of such substitution. The person presenting the prescription shall have the right to refuse the substitution. Upon request the pharmacist shall relate the retail price difference between the brand name and the drug substituted for it.

(k) Every pharmacy shall post in a prominent place that is in clear and unobstructed public view, at or near the place where prescriptions are dispensed, a sign which shall read: “West Virginia law requires pharmacists to substitute a less expensive generic named therapeutically equivalent drug for a brand name drug, if available, unless you or your physician direct otherwise.” The sign shall be printed with lettering of at least one and one-half inches in height with appropriate margins and spacing as prescribed by the West Virginia board of pharmacy.

(l) The West Virginia board of pharmacy shall promulgate rules and regulations setting standards for substituted drug products, obtaining compliance with the provisions of this section and enforcing the provisions of this section. Any person shall have the right to file a complaint with the West Virginia board
of pharmacy regarding any violation of the provisions
of this article. Such complaints shall be investigated by
the board of pharmacy.

Fifteen days after the board has notified, by regis-
tered mail, a person, firm, corporation or
copartnership that such person, firm, corporation or
copartnership is suspected of being in violation of a
provision of this section, the board shall hold a hearing
on the matter. If, as a result of the hearing, the board
determines that a person, firm, corporation or
copartnership is violating any of the provisions of this
section, it may, in addition to any penalties prescribed
by section twenty-two of this article, suspend or
revoke the permit of any person, firm, corporation or
copartnership to operate a pharmacy or drugstore.

(m) No pharmacist complying with the provisions of
this section shall be liable in any way for the
dispensing of a generic named therapeutically equiva-

cent drug, substituted under the provisions of this
section, unless the generic named therapeutically
equivalent drug was incorrectly substituted.

In no event where the pharmacist substitutes a drug
under the provisions of this section shall the
prescribing physician be liable in any action for loss,
damage, injury or death of any person occasioned by
or arising from the use of the substitute drug unless
the original drug was incorrectly prescribed.

Failure of a practitioner to specify that a specific
brand name is necessary for a particular patient shall
not constitute evidence of negligence unless the
practitioner had reasonable cause to believe that the
health of the patient required the use of a certain
product and no other.
The Joint Committee on Enrolled Bills hereby certifies that the foregoing bill is correctly enrolled.

Frederick L. Parker  
Chairman Senate Committee

F. T. Lotts  
Chairman House Committee

Originated in the Senate.

To take effect July 1, 1989.

Ford C. vitality  
Clerk of the Senate

Donnell J. Kopp  
Clerk of the House of Delegates

President of the Senate

Speaker House of Delegates

The within is approved this the 8th day of March, 1989.

Governor